Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Visceral Adiposity

  • Home
  • Visceral Adiposity
Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
Posted inDiabetes & Endocrinology Gastroenterology news

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

Posted by MedXY By MedXY 01/24/2026
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-month period.
Read More
  • Post-infection Gut-Brain Disorders Affect About 1 in 10 People With DGBI Worldwide, With Distinct Psychological and Regional Patterns
  • PRDM9 Deficiency Identifies a Predominant Molecular Subgroup in Sporadic Hirschsprung Disease and Enables Blood-based Risk Stratification
  • Ultra-Early Remote Ischemic Postconditioning After Thrombectomy Appears Safe but Does Not Improve 90-Day Stroke Recovery
  • Postmenopausal Migraine Signals Higher Ischemic Stroke Risk, Not Hemorrhagic Stroke, in the Women’s Health Initiative
  • Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in